An Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-Receptor Positive/ HER2-Negative Primary Breast Cancer


This cross-sectional study will use different modes of survey administration to examine how the level of harm patients sustain due to a medical error or adverse event influences Minnesota physicians' willingness to disclose them to patients and/or their families. A random sample of 8,000 currently licensed physicians will be selected from the state licensure database to participate in this study.

I'm interested

This study is NOT accepting healthy volunteers

Breast Cancer

Estrogen-Receptor Positive, Goserelin, HER2-Negative, Ki67, Letrozole, Neoadjuvant, Oncotype DX Breast Recurrence Score, Open-Label, Ovarian Suppression, Palbociclib, Premenopausal, Primary

Lauren Aase -
Phase II
See this study on